The benefit of split dosing is improved tolerability and more consistent appetite control, which may indirectly support better adherence and outcomes
Andrew Lee, a clinical spokesperson for the American Academy of Ophthalmology and a neuro-ophthalmologist at the Houston Medical Center, told NBC Los Angeles that although he has patients who developed NAION and were prescribed semaglutide, it remains unclear whether this is a causal association or merely an association alone. Thats because, as that article notes, people with Type 2 diabetes which is nominally required for an Ozempic prescription are at increased risk for vision problems, including NAION
How does bariatric surgery compare to long-term use of GLP-1 medication
The main methods for targeting PCSK9 include inhibition of its binding to LDLRs, downregulation of PCSK9 expression, and interference with the secretion of PCSK9
Safety Comparison# Semaglutide# Well-characterized safety profile across thousands of patients: GI adverse events: 50-70% (mostly mild-moderate, dose-escalation related) Discontinuation due to AEs: ~7% (STEP 1) Boxed warning: Thyroid C-cell tumors (rodent data) Post-marketing signals: Pancreatitis, gallbladder events, ileus (rare) 8+ years of post-marketing surveillance Zovaglutide# Phase 2 safety data (303 patients, 24 weeks): GI adverse events: Present but low severity Discontinuation due to GI AEs: 1.3% (notably low for GLP-1 class) Monthly dosing showed fewer GI events than biweekly dosing No long-term safety data available No post-marketing experience The 1.3% GI-related discontinuation rate is notably lower than typical GLP-1 agonists (5-10%)